BPA Call 36C24823A0010-36C24826N0322
- Veracyte Labs SD Corporation, operating through its Decipher Biosciences division, received a Blanket Purchase Agreement (BPA) call award valued at $184,713.63 from Veterans Integrated Service Network 8 (VISN 8), a civilian agency within the Department of Veterans Affairs. This firm fixed-price contract, awarded February 1, 2024, with completion by January 31, 2025, represents a de-obligation of excess FY2024 funds under the parent BPA for cost-per-test Decipher genomic sequencing services....
- The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) call contract to Veracyte Labs SD Corporation, operating through its Decipher Biosciences, Inc. division, for $294,893.69 to provide the Decipher Prostate Cancer Test. This specialized genomic test analyzes tumor gene expression patterns to help clinicians make more informed treatment decisions for prostate cancer patients, supporting the VA's efforts to deliver precision medicine for veterans. The contract...
- This is a federal contract award to Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc., for DECIPHER PROSTATE CANCER TESTING services. The contract, valued at $3,240.59, was awarded by the Veterans Integrated Service Network 17 (VISN 17) of the Department of Veterans Affairs (VA). This is a Firm Fixed Price Blanket Purchase Agreement (BPA) Call contract under the VA's Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II). The contract does...
- Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc., was awarded a $324,059 delivery order by Veterans Integrated Service Network 2 on October 23, 2025, for the provision of Decipher Prostate Cancer testing services at the Northport Veterans Affairs Medical Center. The contract, which is not set aside for any specific business category, is structured as a firm fixed-price delivery order under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule...
- This federal contract award, valued at $61,571.21, was issued by the Department of Veterans Affairs (VA) to Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc. The contract is a Blanket Purchase Agreement (BPA) call under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II). The contract is for the Decipher Prostate Cancer Testing service, which analyzes tumor gene expression patterns to help clinicians make more informed treatment...
- This delivery order, awarded to Veracyte Labs SD Corporation (a division of Decipher Biosciences, Inc.) on April 15, 2023, represents Option Year 2 of a contract to provide Decipher Prostate Testing services to Veterans Integrated Service Network 10 (VISN 10). The contract, valued at $408,314.34 on a firm fixed-price basis, will be performed in Ann Arbor, Michigan, with an ultimate completion date of November 14, 2025. This award was not subject to any small business set-aside and is established...
- This is a firm fixed price contract awarded by the Veterans Health Administration's Veterans Integrated Service Network 8 (VISN 8) to Veracyte Labs SD Corporation, a division of Veracyte, Inc. The contract, valued at $372,667.85, is for the delivery of the Decipher Prostate Cancer Test, a specialized genomic diagnostic service that analyzes tumor gene expression patterns to help clinicians assess prostate cancer risk and guide treatment decisions. The contract is a Blanket Purchase Agreement...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $49,084.18 firm fixed price delivery order contract to Veracyte Labs SD Corp, a division of Decipher Biosciences, Inc., for prostate cancer testing services. To be performed in San Francisco, California, the contract calls for Decipher Biosciences to provide its Decipher Prostate Cancer Testing to aid in clinical decision making and active surveillance for prostate cancer...
- This is a firm fixed-price contract awarded by the Department of Veterans Affairs (VA) to Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc. The contract, valued at $194,435.40, is a Blanket Purchase Agreement (BPA) call order issued under the VA's Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) contract vehicle. The contract is for Veracyte Labs to provide its proprietary Decipher Prostate Cancer Test, a genomic classifier that...
- This is a firm fixed-price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) to Veracyte Labs SD Corporation, a division of Veracyte, Inc., for the modification of the Decipher Prostate Cancer Testing service. The $64,811.80 contract has an ultimate completion date of November 14, 2026 and is not set aside. Veracyte, a for-profit medical diagnostics company, provides specialized genomic testing services to support precision medicine and personalized...
- Medical Laboratory Testing and Analysis Services (FSS-621-II)Master GSA Schedule
- 36F79721D0019-36C24823A0010Blanket Purchase Agreement
- 36C24823A0010-36C24826N0322BPA Call
Veracyte Labs SD Corporation, operating under its Decipher Biosciences division, was awarded a Blanket Purchase Agreement call valued at $194,435.40 by Veterans Integrated Service Network 8 on February 1, 2026, with performance completion by January 31, 2027. This firm fixed-price contract, which carries no set-aside designation, establishes a cost-per-test pricing structure for Decipher Prostate Cancer genomic testing services to be performed in San Diego, California. The contract operates under the General Services Administration's Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) and supports the Department of Veterans Affairs' precision medicine initiatives for prostate cancer diagnosis and treatment planning across veteran healthcare networks. Veracyte Labs SD Corporation specializes in advanced genomic testing and molecular diagnostic services, with the Decipher Prostate Cancer Test serving as its primary offering for federal healthcare agencies. The company analyzes tumor gene expression patterns to assess cancer risk, aggressiveness, and metastatic potential, enabling clinicians to make informed treatment decisions. This award represents one of multiple delivery orders and blanket purchase agreements the company has received from various Veterans Integrated Service Networks and the Defense Health Agency, with the parent company Veracyte, Inc., headquartered in South San Francisco, maintaining an extensive federal contract portfolio spanning multiple genomic testing applications including thyroid and prostate cancer diagnostics.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $194.4k | 1/29/26 |